Cell Line Development

© GettyImages/PonyWang

Sphere Fluidics closes $40m funding round

By Jane Byrne

Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.

(Image: Getty/wildpixel)

CAR-T for solid tumors drives industry to innovate

By Maggie Lynch

ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.

Catalent commits to ADCs by upping its stake in Redwood

News from Interphex 2014

Catalent commits to ADCs by upping its stake in Redwood

By Dan Stanton

Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers